Tocilizumab: A Therapeutic Option for the Treatment of Cytokine Storm Syndrome in COVID-19

Presently, we need more therapeutic molecules for this COVID-19 outbreak. The severity and mortality of the disease is associated with a high level of release of cytokine in the patients which is known as CRS (cytokine release syndrome) or cytokine storm syndrome. IL-6 is a type of pro-inflammatory...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :Arch Med Res
Главные авторы: Saha, Abinit, Sharma, Ashish Ranjan, Bhattacharya, Manojit, Sharma, Garima, Lee, Sang-Soo, Chakraborty, Chiranjib
Формат: Artigo
Язык:Inglês
Опубликовано: IMSS. Published by Elsevier Inc. 2020
Предметы:
Opinion
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC7241374/
https://ncbi.nlm.nih.gov/pubmed/32482373
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.arcmed.2020.05.009
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы